Biogen Inc. BIIB announced that a new phase III study has been initiated to evaluate its and Eisai’s, the company’s Japan-based partner, anti-amyloid beta monoclonal antibody, BAN2401 to treat preclinical (asymptomatic) Alzheimer’s disease.Other than Biogen, several large pharma companies, including Roche RHHBY, Amgen AMGN, Novartis NVS, Merck, Pfizer, Lilly and AstraZeneca stopped development of their AD candidates in the last few years either due to low possibility of success or safety concerns.